NICE rejection of Afinitor faces appeal from Novartis
This article was originally published in Scrip
Novartis is the second pharmaceutical company this week to announce plans to appeal against NICE, the health technology institute for England and Wales. Today NICE is publishing its second final draft guidance rejecting Afinitor (everolimus) for some patients with advanced kidney cancer, despite the company submitting a revised patient access scheme. Novartis says the interim cancer drugs fund is the best hope for patients who need to access the drug.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.